ArticleOncoTargets and therapy2018
Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- A systematic review and Bayesian meta-analysis assessing intelectin-1 in cancer patients and healthy individuals.Frontiers in oncology · 2024Pooled it
- Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review.Signal transduction and targeted therapy · 2023Pooled it
- Adipocytokines and disease progression in endometrial cancer: a systematic review.Cancer metastasis reviews · 2022Pooled it
- The role of omentin-1 in female reproduction: a critical review.The Journal of reproduction and development · 2026Review
- Omentin-General Overview of Its Role in Obesity, Metabolic Syndrome and Other Diseases; Problem of Current Research State.Biomedicines · 2025Review
- Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers.Cell communication and signaling : CCS · 2024Review
- Review
- Leptin: A Heavyweight Player in Obesity-Related Cancers.Biomolecules · 2023Review
- Review
- Could Vaspin Be a Potential Diagnostic Marker in Endometrial Cancer?International journal of environmental research and public health · 2023Article
- Vaspin accelerates the proliferation, invasion and metastasis of Triple-Negative breast cancer through MiR-33a-5p/ABHD2.Cancer medicine · 2023Article
- The Relationship Between Leptin Receptor Expression and Endometrial Carcinoma; A Case-Control Study.Iranian journal of pathology · 2023Article
- The impact of obesity and adipokines on breast and gynecologic malignancies.Annals of the New York Academy of Sciences · 2022Review
- Article
- Review
- Role of Leptin and Adiponectin in Endometrial Cancer.International journal of molecular sciences · 2022Review
- The Emerging Role of Intelectin-1 in Cancer.Frontiers in oncology · 2022Review
- Models including preoperative plasma levels of angiogenic factors, leptin and IL-8 as potential biomarkers of endometrial cancer.Frontiers in oncology · 2022Article
- Review
- The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdipose tissue is considered an endocrine organ and produces a number of biologically active substances.
aimsTo consider the role that four adipokines - leptin, omentin-1, vaspin, and galectin-3 - play in the diagnosis of endometrium cancer and to investigate the association between serum concentrations of adipose tissue metabolism products and the diagnostics and prognosis in endometrial cancer. PATIENTS AND
methodsThe study included 168 patients with body mass index (BMI) >20 kg/m
resultsA receiver operating characteristic curves test was performed to determine the diagnostic values of the proteins tested. For leptin and galectin-3 the area under the curve (AUC) values were 0.79/0.68, while for vaspin and omentin-1 the AUC values were 0.82/0.86 for all study patients. The final model identified the following independent risk factors: glucose concentration, BMI, waist circumference, leptin, and vaspin concentrations. Diagnostic values of leptin and galectin-3 with regard to differentiation between high (Fédération Internationale de Gynécologie Obstétrique [FIGO] III and IV) and low (FIGO I and II) stages of clinical tumor advancement and prediction of tumor grading (G1 vs G3) based on the AUC curve were 0.82/0.70 and 0.80/0.74. The AUC values for vaspin and omentin-1 with respect to differentiation between histopathological advancement and grading were 0.86/0.81 and 0.83/0.77, respectively. Significantly lower values of mean omentin-1 and vaspin concentrations were also demonstrated in cases of lymphatic vessel invasion, lymph node metastases, or deep endometrial infiltration (
conclusionIt appears that elevated concentrations of leptin, vaspin, and omentin-1 may indicate the presence of endometrial cancer. Furthermore, leptin serum level and vaspin appear to be useful tools in the assessment of clinical staging of endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.